Literature DB >> 20880026

Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure.

H W H van Hees1, Gl Andrade Acuña, M Linkels, P N R Dekhuijzen, L M A Heunks.   

Abstract

BACKGROUND AND
PURPOSE: Diaphragm muscle weakness occurs in patients with heart failure (HF) and is associated with exercise intolerance and increased mortality. Reduced sensitivity of diaphragm fibres to calcium contributes to diaphragm weakness in HF. Here we have investigated the ability of the calcium sensitizer levosimendan to restore the reduced calcium sensitivity of diaphragm fibres from rats with HF. EXPERIMENTAL APPROACH: Coronary artery ligation in rats was used as an animal model for HF. Sham-operated rats served as controls. Fifteen weeks after induction of HF or sham operations animals were killed and muscle fibres were isolated from the diaphragm. Diaphragm fibres were skinned and activated with solutions containing incremental calcium concentrations and 10 µM levosimendan or vehicle (0.02% DMSO). Developed force was measured at each calcium concentration, and force-calcium concentration relationships were plotted. KEY
RESULTS: Calcium sensitivity of force generation was reduced in diaphragm muscle fibres from HF rats, compared with fibres from control rats (P < 0.01). Maximal force generation was ∼25% lower in HF diaphragm fibres than in control fibres (P < 0.05). Levosimendan significantly increased calcium sensitivity of force generation in diaphragm fibres from HF and control rats, without affecting maximal force generation. CONCLUSIONS AND IMPLICATIONS: Levosimendan enhanced the force generating capacity of diaphragm fibres from HF rats by increasing the sensitivity of force generation to calcium concentration. These results provide strong support for testing the effect of calcium sensitizers on diaphragm muscle weakness in patients with HF.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20880026      PMCID: PMC3041247          DOI: 10.1111/j.1476-5381.2010.01048.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

Authors:  M S Nieminen; J Akkila; G Hasenfuss; F X Kleber; L A Lehtonen; V Mitrovic; O Nyquist; W J Remme
Journal:  J Am Coll Cardiol       Date:  2000-11-15       Impact factor: 24.094

2.  Relative contribution of resting haemodynamic profile and lung function to exercise tolerance in male patients with chronic heart failure.

Authors:  P Faggiano; A D'Aloia; A Gualeni; A Giordano
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

3.  Myocardial efficiency during levosimendan infusion in congestive heart failure.

Authors:  H Ukkonen; M Saraste; J Akkila; J Knuuti; M Karanko; H Iida; P Lehikoinen; K Någren; L Lehtonen; L M Voipio-Pulkki
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

4.  Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart.

Authors:  I Edes; E Kiss; Y Kitada; F M Powers; J G Papp; E G Kranias; R J Solaro
Journal:  Circ Res       Date:  1995-07       Impact factor: 17.367

5.  Technique for stabilizing the striation pattern in maximally calcium-activated skinned rabbit psoas fibers.

Authors:  B Brenner
Journal:  Biophys J       Date:  1983-01       Impact factor: 4.033

6.  Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake.

Authors:  Andrew D Michaels; Barry McKeown; Michael Kostal; Kalpesh T Vakharia; Mark V Jordan; Ivor L Gerber; Elyse Foster; Kanu Chatterjee
Journal:  Circulation       Date:  2005-03-21       Impact factor: 29.690

7.  Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance.

Authors:  F J Meyer; M M Borst; C Zugck; A Kirschke; D Schellberg; W Kübler; M Haass
Journal:  Circulation       Date:  2001-05-01       Impact factor: 29.690

Review 8.  Clinical pharmacology of levosimendan.

Authors:  Saila Antila; Stig Sundberg; Lasse A Lehtonen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Diaphragm single-fiber weakness and loss of myosin in congestive heart failure rats.

Authors:  Hieronymus W H van Hees; Henricus F M van der Heijden; Coen A C Ottenheijm; Leo M A Heunks; Cindy J C Pigmans; Freek W A Verheugt; Rene M H J Brouwer; P N Richard Dekhuijzen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-04-20       Impact factor: 4.733

Review 10.  Sarcomere length operating range of vertebrate muscles during movement.

Authors:  T J Burkholder; R L Lieber
Journal:  J Exp Biol       Date:  2001-05       Impact factor: 3.312

View more
  13 in total

1.  Diaphragm muscle weakness in mice is early-onset post-myocardial infarction and associated with elevated protein oxidation.

Authors:  T Scott Bowen; Norman Mangner; Sarah Werner; Stefanie Glaser; Yvonne Kullnick; Andrea Schrepper; Torsten Doenst; Andreas Oberbach; Axel Linke; Leif Steil; Gerhard Schuler; Volker Adams
Journal:  J Appl Physiol (1985)       Date:  2014-10-30

Review 2.  Diaphragm abnormalities in heart failure and aging: mechanisms and integration of cardiovascular and respiratory pathophysiology.

Authors:  Rachel C Kelley; Leonardo F Ferreira
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

3.  Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials.

Authors:  Ravi B Patel; Sanjiv J Shah
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

4.  Levosimendan affects oxidative and inflammatory pathways in the diaphragm of ventilated endotoxemic mice.

Authors:  Willem-Jan M Schellekens; Hieronymus W H van Hees; Marianne Linkels; P N Richard Dekhuijzen; Gert Jan Scheffer; Johannes G van der Hoeven; Leo M A Heunks
Journal:  Crit Care       Date:  2015-03-02       Impact factor: 9.097

5.  Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene.

Authors:  Josine M de Winter; Barbara Joureau; Vasco Sequeira; Nigel F Clarke; Jolanda van der Velden; Ger Jm Stienen; Henk Granzier; Alan H Beggs; Coen Ac Ottenheijm
Journal:  Skelet Muscle       Date:  2015-04-28       Impact factor: 4.912

6.  In vitro effects of levosimendan on muscle of malignant hyperthermia susceptible and non-susceptible swine.

Authors:  Frank Schuster; Stephan Johannsen; Susanne Isbary; Ismail Türkmeneli; Norbert Roewer
Journal:  BMC Anesthesiol       Date:  2018-12-03       Impact factor: 2.217

7.  Effects of levosimendan on respiratory muscle function in patients weaning from mechanical ventilation.

Authors:  Lisanne Roesthuis; Hans van der Hoeven; Christer Sinderby; Tim Frenzel; Coen Ottenheijm; Laurent Brochard; Jonne Doorduin; Leo Heunks
Journal:  Intensive Care Med       Date:  2019-10-01       Impact factor: 17.440

Review 8.  Levosimendan: current data, clinical use and future development.

Authors:  M S Nieminen; S Fruhwald; L M A Heunks; P K Suominen; A C Gordon; M Kivikko; P Pollesello
Journal:  Heart Lung Vessel       Date:  2013

9.  The conventional isoproterenol-induced heart failure model does not consistently mimic the diaphragmatic dysfunction observed in patients.

Authors:  Ignacio Cabrera-Aguilera; Bryan Falcones; Alicia Calvo-Fernández; Begoña Benito; Esther Barreiro; Joaquim Gea; Ramon Farré; Isaac Almendros; Núria Farré
Journal:  PLoS One       Date:  2020-07-30       Impact factor: 3.240

Review 10.  Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.

Authors:  Antoine Herpain; Stefaan Bouchez; Massimo Girardis; Fabio Guarracino; Johann Knotzer; Bruno Levy; Tobias Liebregts; Piero Pollesello; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Fabio Sangalli
Journal:  J Cardiovasc Pharmacol       Date:  2019-01       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.